China SXT Pharmaceuticals (SXTC) Accounts Payables (2018 - 2025)

China SXT Pharmaceuticals' Accounts Payables history runs 8 years deep, the most recent figure standing at $3.3 million for Q3 2025.

• In Q3 2025, Accounts Payables rose 11.77% year-over-year to $3.3 million; the TTM figure through Sep 2025 stood at $3.3 million (up 11.77% YoY), while the FY2025 annual figure was $2.9 million, up 129.59% from the prior year.
• Accounts Payables was $3.3 million for Q3 2025 at China SXT Pharmaceuticals, up from $2.9 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $3.5 million in Q1 2022 to a low of $1.3 million in Q1 2024.
• Historically, Accounts Payables has averaged $2.8 million across 5 years, with a median of $3.1 million in 2021.
• The sharpest annual moves came in 2023 and 2025: Accounts Payables sank 60.96% in 2023, then jumped 129.59% in 2025.
• A 5-year view of Accounts Payables shows it stood at $3.4 million in 2021, then retreated by 2.46% to $3.3 million in 2022, then dropped by 0.89% to $3.2 million in 2023, then decreased by 10.05% to $2.9 million in 2024, then gained by 11.77% to $3.3 million in 2025.
• The last three Accounts Payables figures came in at $3.3 million (Q3 2025), $2.9 million (Q1 2025), and $2.9 million (Q3 2024), per Business Quant data.